CoChat
Sign Up
Cited by 513Nutrition and Health in AgingLiver Disease and TransplantationLiver Disease Diagnosis and Treatment

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis: Sarcopenic obesity and myosteatosis in cirrhosis

Open access
Montano-Loza, Aldo J., Angulo, Paul, Meza-Junco, Judith, Prado, Carla M. M., Sawyer, Michael B., Beaumont, Crystal, Esfandiari, Nina, Ma, Mang, Baracos, Vickie E.·2016·Journal of Cachexia Sarcopenia and Muscle
DOI 10.1002/jcsm.12039PMC PMC4864157
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND AND AIMS: Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients. METHODS: We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body mass index-specific cutoffs. RESULTS: Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%), alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353 had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.44-2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02-1.07, P = 0.04) were associated with mortality. CONCLUSIONS: Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcsm.12039

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Venn diagram illustrating the association between sarcopenia, myosteatosis and obesity.
Figure 1 Venn diagram illustrating the association between sarcopenia, myosteatosis and obesity.CC BY-NC-ND · PubMed Central
Figure 2 Computed tomography images used for the muscularity assessment of patients with cirrhosis. Comparison of two cirrhotic patients with severe obesity. (A) Male patient at the left had sarcopenic obesity (BMI 47 kg/m2, L3 SMI 51 cm2/m2), whereas a female patient at the right (B) had no sarcopenia (BMI 42 kg/m2, L3 SMI 49 cm2/m2). Computed tomography images used for the muscle attenuation assessment of patients with cirrhosis and comparison of two cirrhotic patients with similar BMI (28 kg/m2). (C) Patient at the left had low mean muscle attenuation (21 HU), whereas the patient at the right (D) had normal mean muscle attenuation (40 HU).
Figure 2 Computed tomography images used for the muscularity assessment of patients with cirrhosis. Comparison of two cirrhotic patients with severe obesity. (A) Male patient at the left had sarcopenic obesity (BMI 47 kg/m2, L3 SMI 51 cm2/m2), whereas a female patient at the right (B) had no sarcopenia (BMI 42 kg/m2, L3 SMI 49 cm2/m2). Computed tomography images used for the muscle attenuation assessment of patients with cirrhosis and comparison of two cirrhotic patients with similar BMI (28 kg/m2). (C) Patient at the left had low mean muscle attenuation (21 HU), whereas the patient at the right (D) had normal mean muscle attenuation (40 HU).CC BY-NC-ND · PubMed Central
Figure 3 Kaplan–Meier curve indicating the survival of patients with sarcopenia (—), sarcopenic obesity (‐‐), myosteatosis (‐‐) and without muscular abnormalities (—). The 6‐month probability of survival was 72%, 69%, 76% and 91%, respectively (P < 0.001, log‐rank test). The 1‐year probability of survival was 62%, 59%, 68%, and 85% in these same groups, respectively.
Figure 3 Kaplan–Meier curve indicating the survival of patients with sarcopenia (—), sarcopenic obesity (‐‐), myosteatosis (‐‐) and without muscular abnormalities (—). The 6‐month probability of survival was 72%, 69%, 76% and 91%, respectively (P < 0.001, log‐rank test). The 1‐year probability of survival was 62%, 59%, 68%, and 85% in these same groups, respectively.CC BY-NC-ND · PubMed Central
Figure 4 Percentage of mortality related to liver failure, sepsis, hepatocellular carcinoma progression, variceal bleeding, hepatorenal syndrome and others in cirrhotic patients with (A) sarcopenia, (B) myosteatosis and (C) sarcopenic obesity. GI, gastrointestinal; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome.
Figure 4 Percentage of mortality related to liver failure, sepsis, hepatocellular carcinoma progression, variceal bleeding, hepatorenal syndrome and others in cirrhotic patients with (A) sarcopenia, (B) myosteatosis and (C) sarcopenic obesity. GI, gastrointestinal; HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 513

Related

See all

Metadata

Authors
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E.
Affiliations
  • Division of Gastroenterology & Liver Unit; University of Alberta Hospital; Edmonton Alberta Canada
  • University of Kentucky HealthCare (US)
  • Department of Oncology; Cross Cancer Institute; Edmonton Alberta Canada
  • University of Alberta (CA)
  • Cross Cancer Institute (CA)
  • Alberta Hospital Edmonton (CA)
ORCID
Venue
Journal of Cachexia Sarcopenia and Muscle
Publisher
Wiley
Published
2015-06-09
Volume
7
Issue
2
Pages
126-135
ISSN
2190-5991 (ISSN-L)
DOI
10.1002/jcsm.12039
PMC
PMC4864157
OpenAlex
W1490232555
Cited by
512
References
43
Citations by year
2026: 29 · 2025: 34 · 2024: 67 · 2023: 67 · 2022: 78 · 2021: 53 · 2020: 48 · 2019: 53 · 2018: 48 · 2017: 26 · 2016: 4 · 2015: 3
FWCI
19.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cachexia Sarcopenia and Muscle (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc-nd)
Funders
American College of Gastroenterology Institute 2011
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
myosteatosis, sarcopenia, liver cirrhosis, mortality, skeletal muscle, hepatic steatosis, prognostic factors, hepatitis C, alcoholic cirrhosis, nonalcoholic steatohepatitis, autoimmune liver disease, hepatitis B, body mass index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review